Text Size
Trial record 1 of 2 for:    Open Studies | "Foodborne Diseases"
Previous Study | Return to List | Next Study

Study of Human Botulism Immunoglobulin in Infants With Botulism

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2000 by FDA Office of Orphan Products Development.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
California Department of Health Services
Information provided by:
FDA Office of Orphan Products Development
ClinicalTrials.gov Identifier:
NCT00004401
First received: October 18, 1999
Last updated: June 23, 2005
Last verified: March 2000
History of Changes
  Purpose

OBJECTIVES: I. Determine the safety of human botulism immune globulin (BIG) in patients with infant botulism by monitoring side effects (e.g., rash, fever, hypotension, and anaphylaxis).

II. Assess the efficacy of BIG in these patients by monitoring disease severity, incidence of complications (respiratory arrest, aspiration, pneumonia, etc.), and length of hospital stay.


Condition Intervention
Infant Botulism
Botulism
 Drug: botulism immune globulin

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by FDA Office of Orphan Products Development:

Estimated Enrollment: 120
Study Start Date: January 1998
Detailed Description:

PROTOCOL OUTLINE: This is an open label, multicenter study. Patients should begin therapy within 72 hours of hospital admission, but may receive human botulism immunoglobulin (BIG) in certain circumstances after 72 hours. Patients receive (BIG) IV. Patients are monitored for side effects, disease severity, complications, and length of hospital stay.

Patients are followed at 2 weeks after treatment, then every 4 weeks for 6 months.

  Eligibility

Ages Eligible for Study:   up to 1 Year
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

  • Clinical diagnosis of infant botulism in previously healthy infant
  • Bulbar palsies
  • Constipated Lethargy
  • Diminished head control
  • Poor feeding
  • Generalized weakness and hypotonia
  • Weak cry
  • Afebrile (unless secondary infection present)
  • Subacute to acute onset
  • Normal electrolytes
  • Any patient eligible provided no treatment available for life-threatening condition
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00004401

Locations
United States, California
California Department of Health Services Recruiting
Berkeley, California, United States, 94704-1011
Contact: Stephen S. Arnon     510-540-2646        
Sponsors and Collaborators
FDA Office of Orphan Products Development
California Department of Health Services
Investigators
Study Chair: Stephen S. Arnon California Department of Health Services
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00004401     History of Changes
Other Study ID Numbers: 199/13253, CDHS-FDU000476
Study First Received: October 18, 1999
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Keywords provided by FDA Office of Orphan Products Development:
bacterial infection
clostridium infection
immunologic disorders and infectious disorders
infant botulism
rare disease

Additional relevant MeSH terms:
Foodborne Diseases
Botulism
Clostridium Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Neuromuscular Junction Diseases
Neuromuscular Diseases
Nervous System Diseases
 Neurotoxicity Syndromes
Poisoning
Substance-Related Disorders
Antibodies
Immunoglobulins
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on June 17, 2013